Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 762

1.

Unresectable metastatic colorectal cancer patient cured with cetuximab-based chemotherapy: a case report with new molecular insights.

Cohen R, Sroussi M, Pilati C, Houry S, Laurent-Puig P, André T.

J Gastrointest Oncol. 2018 Aug;9(4):E23-E27. doi: 10.21037/jgo.2018.05.10.

2.

Exceptional response to FOLFIRINOX in a patient with pancreatic cancer and a germline RAD51C mutation.

Palacio S, Pollack T, Silva-Smith R, Sussman DA, Hosein PJ.

J Gastrointest Oncol. 2018 Aug;9(4):E19-E22. doi: 10.21037/jgo.2018.03.11.

3.

The gut microbiome and colorectal cancer: a review of bacterial pathogenesis.

Dahmus JD, Kotler DL, Kastenberg DM, Kistler CA.

J Gastrointest Oncol. 2018 Aug;9(4):769-777. doi: 10.21037/jgo.2018.04.07. Review.

4.

Concurrent chemoradiation for resected gall bladder cancers and cholangiocarcinomas.

Fareed MM, DeMora L, Esnaola NF, Denlinger CS, Karachristos A, Ross EE, Hoffman J, Meyer JE.

J Gastrointest Oncol. 2018 Aug;9(4):762-768. doi: 10.21037/jgo.2018.05.09.

5.

Is there an optimal staging system or liver reserve model that can predict outcome in hepatocellular carcinoma?

Jaruvongvanich V, Sempokuya T, Wong L.

J Gastrointest Oncol. 2018 Aug;9(4):750-761. doi: 10.21037/jgo.2018.05.11.

6.

Efficacy of bi-monthly hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma.

Moriya K, Namisaki T, Sato S, Douhara A, Furukawa M, Kawaratani H, Kaji K, Kitade M, Shimozato N, Sawada Y, Seki K, Saikawa S, Takaya H, Akahane T, Mitoro A, Okura Y, Yamao J, Yoshiji H.

J Gastrointest Oncol. 2018 Aug;9(4):741-749. doi: 10.21037/jgo.2018.05.13.

7.

Stereotactic body radiation therapy following transarterial chemoembolization for unresectable hepatocellular carcinoma.

Buckstein M, Kim E, Fischman A, Blacksburg S, Facciuto M, Schwartz M, Rosenzweig K.

J Gastrointest Oncol. 2018 Aug;9(4):734-740. doi: 10.21037/jgo.2018.05.01.

8.

Overexpression of SSH1 in gastric adenocarcinoma and its correlation with clinicopathological features.

Daryabari SS, Safaralizadeh R, Hosseinpourfeizi M, Moaddab Y, Shokouhi B.

J Gastrointest Oncol. 2018 Aug;9(4):728-733. doi: 10.21037/jgo.2018.03.09.

9.

Clinicopathologic features and outcomes of gastrointestinal stromal tumors arising from the esophagus and gastroesophageal junction.

Briggler AM, Graham RP, Westin GF, Folpe AL, Jaroszewski DE, Okuno SH, Halfdanarson TR.

J Gastrointest Oncol. 2018 Aug;9(4):718-727. doi: 10.21037/jgo.2018.04.06.

10.

Role of lymph node ratio in selection of adjuvant treatment (chemotherapy vs. chemoradiation) in patients with resected gastric cancer.

Jabo B, Selleck MJ, Morgan JW, Lum SS, Bahjri K, Aljehani M, Garberoglio CA, Reeves ME, Namm JP, Solomon NL, Luca F, Yang G, Senthil M.

J Gastrointest Oncol. 2018 Aug;9(4):708-717. doi: 10.21037/jgo.2018.05.12.

11.

Retrospective comparison of the efficacy and the toxicity of standard and modified FOLFIRINOX regimens in patients with metastatic pancreatic adenocarcinoma.

de Jesus VHF, Camandaroba MPG, Donadio MDS, Cabral A, Muniz TP, de Moura Leite L, Sant'Ana LF.

J Gastrointest Oncol. 2018 Aug;9(4):694-707. doi: 10.21037/jgo.2018.04.02.

12.

Pencil beam scanning versus passively scattered proton therapy for unresectable pancreatic cancer.

Chuong M, Badiyan SN, Yam M, Li Z, Langen K, Regine W, Morris C, Snider J 3rd, Mehta M, Huh S, Rutenberg M, Nichols RC.

J Gastrointest Oncol. 2018 Aug;9(4):687-693. doi: 10.21037/jgo.2018.03.14.

13.

Chemotherapy re-challenge response rate in metastatic colorectal cancer.

Chambers AE, Frick J, Tanner N, Gerkin R, Kundranda M, Dragovich T.

J Gastrointest Oncol. 2018 Aug;9(4):679-686. doi: 10.21037/jgo.2018.04.08.

14.

The incidence of colorectal cancer in patients with previously removed polyp(s)-a cross-sectional study.

Loffeld RJLF, Liberov B, Dekkers PEP.

J Gastrointest Oncol. 2018 Aug;9(4):674-678. doi: 10.21037/jgo.2018.05.02.

15.

Outcome and factors associated with aborted cytoreduction for peritoneal carcinomatosis.

Guerrero W, Munene G, Dickson PV, Stiles ZE, Mays J, Davidoff AM, Glazer ES, Shibata D, Deneve JL.

J Gastrointest Oncol. 2018 Aug;9(4):664-673. doi: 10.21037/jgo.2018.04.05.

17.

Neoadjuvant PET and MRI-based intensity modulated radiotherapy leads to less toxicity and improved pathologic response rates in locally advanced rectal cancer.

David JM, Gresham G, Jabbour SK, Deek M, Thomassian S, Robertson JM, Newman NB, Herman JM, Osipov A, Kabolizadeh P, Tuli R.

J Gastrointest Oncol. 2018 Aug;9(4):641-649. doi: 10.21037/jgo.2018.03.10.

18.

The value of oxaliplatin in the systemic treatment of locally advanced rectal cancer.

Martín-Aragón T, Serrano J, Benedí J, Meiriño RM, García-Alonso P, Calvo FA.

J Gastrointest Oncol. 2018 Aug;9(4):631-640. doi: 10.21037/jgo.2018.06.02.

19.

Impact of intensity modulated radiation therapy on survival in anal cancer.

Jhaveri J, Rayfield L, Liu Y, Chowdhary M, Tian S, Cassidy RJ, Gillespie T, Patel PR, Landry JC, Patel KR.

J Gastrointest Oncol. 2018 Aug;9(4):618-630. doi: 10.21037/jgo.2018.05.07.

20.

Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition.

Fabrizio DA, George TJ Jr, Dunne RF, Frampton G, Sun J, Gowen K, Kennedy M, Greenbowe J, Schrock AB, Hezel AF, Ross JS, Stephens PJ, Ali SM, Miller VA, Fakih M, Klempner SJ.

J Gastrointest Oncol. 2018 Aug;9(4):610-617. doi: 10.21037/jgo.2018.05.06.

Supplemental Content

Loading ...
Support Center